Compare TBPH & EVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBPH | EVV |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2013 | 2003 |
| Metric | TBPH | EVV |
|---|---|---|
| Price | $19.26 | $9.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $27.80 | N/A |
| AVG Volume (30 Days) | ★ 386.5K | 291.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $70.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.66 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $8.81 |
| 52 Week High | $21.03 | $10.41 |
| Indicator | TBPH | EVV |
|---|---|---|
| Relative Strength Index (RSI) | 45.07 | 46.88 |
| Support Level | $18.27 | $9.84 |
| Resistance Level | $19.04 | $10.01 |
| Average True Range (ATR) | 0.91 | 0.04 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 23.72 | 28.88 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.